Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Galidesivir

Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM[1][2][3].

Product Specifications

CAS Number

249503-25-1

Product Name Alternative

BCX4430; Immucillin-A

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

DNA/RNA Synthesis; Filovirus; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/BCX4430-freebase.html

Purity

99.29

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O

Molecular Formula

C11H15N5O3

Molecular Weight

265.27

Precautions

H302, H315, H319

References & Citations

[1]Elfiky AA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278 against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) : A molecular docking study. Life Sci. 2020 Mar 25:117592.|[2]Taylor R, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9 (3) :220-226.|[3]Warren TK, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508 (7496) :402-405.|[4]Julander JG, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014;58 (11) :6607-6614.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Phase 1

Citation 01

Antiviral Res. 2017 Jun:142:63-67.|Biomed Pharmacother. 2025 Apr 28:187:118104.|bioRxiv. 2025 January 29.|bioRxiv. 2025 Sep 22.|Exp Ther Med. 2016 Sep;12 (3) :1812-1816. |Microorganisms. 2021 Mar 31;9 (4) :734.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Virology. 2023 Aug:585:21-31.|Viruses. 2020 Jun 10;12 (6) :628.|Antimicrob Agents Chemother. 2019 Feb 26;63 (3) :e02093-18.|Antiviral Res. 2017 Jun:142:63-67.|bioRxiv. 2025 April 22.|J AOAC Int. 2024 Jun 13:qsae047.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

Ablim1 ORF Vector (Mouse) (pORF)
ORF037851 1.0 µg DNA

Ablim1 ORF Vector (Mouse) (pORF)

Sign In for Pricing
View Details
NCAPG2, ID (NCAPG2, LUZP5, Condensin-2 complex subunit G2, Chromosome-associated protein G2, Leucine zipper protein 5, Non-SMC condensin II complex subunit G2)
038823 200 µL

NCAPG2, ID (NCAPG2, LUZP5, Condensin-2 complex subunit G2, Chromosome-associated protein G2, Leucine zipper protein 5, Non-SMC condensin II complex subunit G2)

Sign In for Pricing
View Details
R3HCC1 Recombinant Protein Antigen
NBP1-90528PEP 0.1 mL

R3HCC1 Recombinant Protein Antigen

Sign In for Pricing
View Details
Integrin Beta 6 (ITGb6) Monoclonal Antibody
CAU36940-01 100 µL

Integrin Beta 6 (ITGb6) Monoclonal Antibody

Sign In for Pricing
View Details
Integrin Beta 6 (ITGb6) Monoclonal Antibody
CAU36940-02 200 µL

Integrin Beta 6 (ITGb6) Monoclonal Antibody

Sign In for Pricing
View Details
Integrin Beta 6 (ITGb6) Monoclonal Antibody
CAU36940-03 1 mL

Integrin Beta 6 (ITGb6) Monoclonal Antibody

Sign In for Pricing
View Details